Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Abcam plc is a biotechnology business based in the US. Abcam shares (ABCM) are listed on the NASDAQ and all prices are listed in US Dollars. Abcam employs 1,650 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Large Accounts
| Latest market close | $22.90 |
|---|---|
| 52-week range | $17.14 - $24.69 |
| 50-day moving average | $20.76 |
| 200-day moving average | $19.97 |
| Wall St. target price | $1,639.13 |
| PE ratio | 220.9184 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.10 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $22.9 from 2021-10-21
| 1 week (2021-10-15) | 5.77% |
|---|---|
| 1 month (2021-09-22) | 8.84% |
| 3 months (2021-07-22) | 26.80% |
| 6 months (2021-04-22) | 12.37% |
| 1 year (2020-10-22) | 15.95% |
|---|---|
| 2 years (2019-10-18) | N/A |
| 3 years (2018-10-18) | N/A |
| 5 years (2016-10-18) | N/A |
Valuing Abcam stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abcam's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abcam's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 221x. In other words, Abcam shares trade at around 221x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Abcam's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Abcam's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $61 million.
The EBITDA is a measure of a Abcam's overall financial performance and is widely used to measure a its profitability.
To put Abcam's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $297.7 million |
|---|---|
| Operating margin TTM | 11.29% |
| Gross profit TTM | $211.8 million |
| Return on assets TTM | 2.57% |
| Return on equity TTM | 2.85% |
| Profit margin | 5.44% |
| Book value | $2.81 |
| Market capitalisation | $4.9 billion |
TTM: trailing 12 months
There are currently 129,161 Abcam shares held short by investors – that's known as Abcam's "short interest". This figure is 0.3% up from 128,737 last month.
There are a few different ways that this level of interest in shorting Abcam shares can be evaluated.
Abcam's "short interest ratio" (SIR) is the quantity of Abcam shares currently shorted divided by the average quantity of Abcam shares traded daily (recently around 52291.902834008). Abcam's SIR currently stands at 2.47. In other words for every 100,000 Abcam shares traded daily on the market, roughly 2470 shares are currently held short.
To gain some more context, you can compare Abcam's short interest ratio against those of similar companies.
However Abcam's short interest can also be evaluated against the total number of Abcam shares, or, against the total number of tradable Abcam shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abcam's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Abcam shares in existence, roughly 0 shares are currently held short) or 0.0007% of the tradable shares (for every 100,000 tradable Abcam shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abcam.
Find out more about how you can short Abcam stock.
We're not expecting Abcam to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Abcam's shares have ranged in value from as little as $17.14 up to $24.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abcam's is 0.5824. This would suggest that Abcam's shares are less volatile than average (for this exchange).
To put Abcam's beta into context you can compare it against those of similar companies.
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; cell line and lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. It also sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
